Search for Clinical Trial Results
Myopia - 71 Studies Found
Status | Study |
Completed |
Study Name: Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds Condition: High Myopia Date: 2007-11-26 Interventions: Drug: PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds Mitomycin |
Completed |
Study Name: Study of Theories About Myopia Progression (STAMP) Condition: Myopia Date: 2006-06-07 Interventions:
|
Recruiting |
Study Name: The Relationship Between Structure and Visual Function in Myopia Foveoschisis Condition: High Myopia Date: 2016-09-04 Interventions: Procedure: macular buckling surgery Participants with high myopia foveoschisis are scheduled to macular |
Enrolling by invitation |
Study Name: Time Outdoors as an Intervention for Myopia in Children Condition: Myopia Date: 2016-11-21 Interventions:
|
Recruiting |
Study Name: Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial Condition: Myopia Date: 2014-06-29 Interventions:
|
Recruiting |
Study Name: Genomewide Screening of Pathological Myopia Condition: Pathological Myopia Date: 2005-09-09 |
Recruiting |
Study Name: Early Vitrectomy for Macular Tractional Maculopathy Condition: Myopia, Degenerative Date: 2010-04-30 Interventions: Procedure: Early vitrectomy Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine gree |
Completed |
Study Name: Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia Condition: Myopia, Degenerative Date: 2013-07-10 Interventions:
|
Completed |
Study Name: Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Condition:
Date: 2011-08-22 Interventions: Drug: Combretastatin A-4 Phosphate Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- |
Completed |
Study Name: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen Condition: Choroidal Neovascularisation Date: 2009-12-21 Interventions: Drug: ranibizumab 0.5mg |